| Basics |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States.
|
| IPO Date: |
October 16, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$47.69M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.63 | 3.90%
|
| Avg Daily Range (30 D): |
$0.28 | 3.71%
|
| Avg Daily Range (90 D): |
$0.29 | 3.90%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.7M |
| Avg Daily Volume (30 D): |
.05M |
| Avg Daily Volume (90 D): |
.06M |
| Trade Size |
| Avg Trade Size (Sh.): |
144 |
| Avg Trade Size (Sh.) (30 D): |
100 |
| Avg Trade Size (Sh.) (90 D): |
100 |
| Institutional Trades |
| Total Inst.Trades: |
2,724 |
| Avg Inst. Trade: |
$2.22M |
| Avg Inst. Trade (30 D): |
$.52M |
| Avg Inst. Trade (90 D): |
$.52M |
| Avg Inst. Trade Volume: |
.01M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2M |
| Avg Closing Trade (30 D): |
$4.55M |
| Avg Closing Trade (90 D): |
$4.55M |
| Avg Closing Volume: |
6.14K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-2.57
|
$3.53
|
$-.07
|
|
Diluted EPS
|
$-2.6
|
$3.5
|
$-.07
|
|
Revenue
|
$ 199.73M
|
$ 98.15M
|
$ 32.75M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -15.64M
|
$ 38.01M
|
$ -12.69M
|
|
Operating Income / Loss
|
$ -13.39M
|
$ 38.8M
|
$ -12.2M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -21.25M
|
$ -11.19M
|
$ -21.42M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 20, 2024:
1:25
|
|
|
|
